NasdaqGS - Delayed Quote USD
Immunovant, Inc. (IMVT)
At close: October 18 at 4:00 PM EDT
After hours: October 18 at 7:45 PM EDT
Insider Purchases Last 6 Months
Shares | Transactions | |
---|---|---|
Purchases | 0 | 0 |
Sales | -- | 0 |
Net Shares Purchased (Sold) | 0 | 0 |
Total Insider Shares Held | 81.7M | -- |
% Net Shares Purchased (Sold) | -- | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
Shares | |
---|---|
Net Shares Purchased (Sold) | -- |
% Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
Insider | Transaction | Type | Value | Date |
---|---|---|---|---|
SALZMANN PETER Chief Executive Officer | Sale at price 29.56 per share. | Direct | 131,838 | Oct 9, 2024 |
BARNETT EVA RENEE Chief Financial Officer | Sale at price 29.56 per share. | Direct | 152,589 | Oct 9, 2024 |
LEVINE MARK S Officer | Sale at price 31.84 - 32.32 per share. | Direct | 104,976 | Aug 21, 2024 |
BUTCHKO JULIA G Officer | Sale at price 31.84 - 32.32 per share. | Direct | 96,437 | Aug 21, 2024 |
SALZMANN PETER Chief Executive Officer | Sale at price 31.84 - 32.32 per share. | Direct | 480,052 | Aug 21, 2024 |
MACIAS WILLIAM L Officer | Sale at price 31.84 - 32.32 per share. | Direct | 96,437 | Aug 21, 2024 |
BARNETT EVA RENEE Chief Financial Officer | Sale at price 31.84 - 32.32 per share. | Direct | 120,045 | Aug 21, 2024 |
LEVINE MARK S Officer | Sale at price 27.76 per share. | Direct | 111,456 | Jul 24, 2024 |
STOUT JAY S Chief Technology Officer | Sale at price 27.76 per share. | Direct | 78,089 | Jul 24, 2024 |
GEFFNER MICHAEL Officer | Sale at price 27.76 per share. | Direct | 95,939 | Jul 24, 2024 |
LEVINE MARK S Officer | Sale at price 29.64 - 30.55 per share. | Direct | 74,382 | Jul 17, 2024 |
BUTCHKO JULIA G Officer | Sale at price 29.64 - 30.55 per share. | Direct | 85,132 | Jul 17, 2024 |
SALZMANN PETER Chief Executive Officer | Sale at price 29.64 - 30.55 per share. | Direct | 257,888 | Jul 17, 2024 |
MACIAS WILLIAM L Officer | Sale at price 29.64 - 30.55 per share. | Direct | 90,386 | Jul 17, 2024 |
BARNETT EVA RENEE Chief Financial Officer | Sale at price 29.64 - 30.55 per share. | Direct | 92,733 | Jul 17, 2024 |
BUTCHKO JULIA G Officer | Sale at price 28.06 per share. | Direct | 42,848 | Jul 9, 2024 |
SALZMANN PETER Chief Executive Officer | Sale at price 28.06 per share. | Direct | 129,609 | Jul 9, 2024 |
BARNETT EVA RENEE Chief Financial Officer | Sale at price 28.06 per share. | Direct | 133,201 | Jul 9, 2024 |
LEVINE MARK S Officer | Sale at price 29.65 per share. | Direct | 96,125 | May 22, 2024 |
BUTCHKO JULIA G Officer | Sale at price 29.65 per share. | Direct | 96,274 | May 22, 2024 |
SALZMANN PETER Chief Executive Officer | Sale at price 29.65 per share. | Direct | 479,233 | May 22, 2024 |
MACIAS WILLIAM L Officer | Sale at price 29.65 per share. | Direct | 96,274 | May 22, 2024 |
BARNETT EVA RENEE Chief Financial Officer | Sale at price 29.65 per share. | Direct | 119,845 | May 22, 2024 |
LEVINE MARK S Officer | Sale at price 28.90 per share. | Direct | 114,531 | Apr 24, 2024 |
STOUT JAY S Chief Technology Officer | Sale at price 28.90 per share. | Direct | 209,207 | Apr 24, 2024 |
GEFFNER MICHAEL Officer | Sale at price 28.90 per share. | Direct | 94,243 | Apr 24, 2024 |
LEVINE MARK S Officer | Sale at price 28.80 - 29.94 per share. | Direct | 285,554 | Apr 17, 2024 |
BUTCHKO JULIA G Officer | Sale at price 28.80 - 29.94 per share. | Direct | 293,923 | Apr 17, 2024 |
SALZMANN PETER Chief Executive Officer | Sale at price 28.80 - 29.94 per share. | Direct | 990,269 | Apr 17, 2024 |
MACIAS WILLIAM L Officer | Sale at price 28.80 - 29.94 per share. | Direct | 240,602 | Apr 17, 2024 |
BARNETT EVA RENEE Chief Financial Officer | Sale at price 28.80 - 29.94 per share. | Direct | 356,049 | Apr 17, 2024 |
BUTCHKO JULIA G Officer | Sale at price 31.18 per share. | Direct | 32,833 | Apr 9, 2024 |
SALZMANN PETER Chief Executive Officer | Sale at price 31.18 per share. | Direct | 149,882 | Apr 9, 2024 |
BARNETT EVA RENEE Chief Financial Officer | Sale at price 31.18 per share. | Direct | 115,023 | Apr 9, 2024 |
MIGAUSKY GEORGE V Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Apr 2, 2024 |
FROMKIN ANDREW J Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Apr 2, 2024 |
LEVINE MARK S Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Apr 2, 2024 |
PANDE ATUL Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Apr 2, 2024 |
STOUT JAY S Chief Technology Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Apr 2, 2024 |
TORTI FRANK M Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Apr 2, 2024 |
HUGHES DOUGLAS J Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Apr 2, 2024 |
BUTCHKO JULIA G Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Apr 2, 2024 |
SALZMANN PETER Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Apr 2, 2024 |
MACIAS WILLIAM L Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Apr 2, 2024 |
BARNETT EVA RENEE Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Apr 2, 2024 |
GEFFNER MICHAEL Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Apr 2, 2024 |
LEVINE MARK S Officer | Sale at price 36.15 per share. | Direct | 77,144 | Feb 22, 2024 |
BUTCHKO JULIA G Officer | Sale at price 36.15 per share. | Direct | 77,578 | Feb 22, 2024 |
SALZMANN PETER Chief Executive Officer | Sale at price 36.15 per share. | Direct | 486,362 | Feb 22, 2024 |
MACIAS WILLIAM L Officer | Sale at price 36.15 per share. | Direct | 80,289 | Feb 22, 2024 |
Related Tickers
AGIO Agios Pharmaceuticals, Inc.
45.50
+3.08%
RVMD Revolution Medicines, Inc.
50.43
+0.86%
KROS Keros Therapeutics, Inc.
61.25
+0.26%
ROIV Roivant Sciences Ltd.
11.92
+0.08%
CYTK Cytokinetics, Incorporated
54.97
+0.81%
ARGX argenx SE
565.00
+3.89%
BBIO BridgeBio Pharma, Inc.
26.02
-0.65%
ASND Ascendis Pharma A/S
129.90
+2.56%
IDYA IDEAYA Biosciences, Inc.
30.54
-0.49%
DNLI Denali Therapeutics Inc.
27.59
+0.62%